XKXiangying Kong

Xiangying Kong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiangying Kong has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Jingbo Wang

    State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing, China

    6 shared publications
  • Xiaohui Su

    Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China

    6 shared publications
  • Mingzhu Qi

    State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing, China

    5 shared publications
  • Xiaohui Su

    Institute of Chinese Materia Medica China Academy of Chinese Medical Sciences Beijing China

    5 shared publications
  • Fengyu Huang

    State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing, China

    4 shared publications
  • Na Lin

    Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China

    4 shared publications

Latest Publications

  • Open Access

    Cross‐Organ Multi‐Omics Profiling of Systemic Alterations in 5xFAD Mice and Changes Associated with Huanglian Jiedu Decoction Treatment

    by Wenya Gao, Jing Gao, Xiaohui Su, Xiangying Kong, Xiaolu Wei, Tunan Ding, Tiantian Guo, Shuangrong Gao, Yanyan Zhou, Junyi Zhou, et al.

    Alzheimer's disease (AD) is increasingly recognized as a systemic disorder involving metabolic abnormalities beyond the brain, but links between hepatic alterations and neuroinflammation remain unclear. We integrated behavioral, histopathological, transcriptomic, proteomic, phosphoproteomic, and metabolomic analyses in male mice assigned to WT ( n = 15), AD ( n = 16), high‐dose HLJDD ( n = 16), low‐dose HLJDD ( n = 11), and donepezil ( n = 10) groups and treated for 10 weeks. Longitudinal behavioral data were analyzed using repeated‐measures models, and omics p ‐values were adjusted using the Benjamini–Hochberg FDR procedure. Cognitive impairment, glial activation, and neuroinflammation were accompanied by hepatic metabolic disturbances and alterations in insulin signaling and energy metabolism, implicating PPAR and PI3K/Akt‐related processes. HLJDD, particularly at the high dose, improved behavioral and neuropathological outcomes and shifted abnormalities in TCA‐cycle metabolites, amino acid neurotransmitters, and oxidative balance toward WT levels. To assess hepatocyte contributions to microglial inflammation, we established an AML12–BV2 conditioned‐medium model with hepatocyte PPAR‐γ knockdown. Conditioned medium from LPS/HLJDD‐cotreated AML12 cells elicited lower inflammatory responses in BV2 cells than medium from LPS‐treated hepatocytes. PPAR‐γ knockdown attenuated this effect, supporting a hepatocyte PPAR‐γ‐dependent contribution to microglial regulation and further investigation of hepatic involvement in HLJDD‐associated neuroprotection.

  • Open Access

    Astragali Radix–Chuanxiong Rhizoma mitigates ischemic stroke by inhibiting NET formation via the C5a/C5aR1 pathway

    by Zhuohang Li, Mingzhu Qi, Sheng Zhang, Helan Huang, Peiping Chen, Fengyu Huang, Xinzhuo Zhang, Jingbo Wang, Changyue Song, Qian Wang, et al.

    Background: Ischemic stroke (IS) is a leading cause of death and disability worldwide, posing a serious threat to human health. The herbal pair Astragali Radix–Chuanxiong Rhizoma (HQ–CX) is commonly used in the treatment of IS. However, the synergistic effects and underlying mechanisms of this herbal combination remain unclear. Objective: This study aimed to evaluate the therapeutic effects of the HQ–CX herbal pair on IS and to investigate its underlying mechanisms. Methods: A rat model of middle cerebral artery occlusion (MCAO) combined with Qi deficiency and blood stasis syndrome (QDBS) was established. The effects of HQ–CX on QDBS-MCAO rats, including improvements in QDBS symptoms, neurological function, and blood flow recovery in the ischemic area, were assessed by Qi deficiency syndrome score, blood stasis syndrome score, modified neurological severity score, cerebral blood flow measurement, and Nissl staining. Transcriptome analysis was conducted to predict the molecular mechanisms underlying the therapeutic effects of HQ–CX in IS. Additional experimental techniques, including enzyme-linked immunosorbent assay, immunofluorescence, Western blot analysis, and treatment with the pharmacological inhibitor deoxyribonuclease I, were employed to validate the efficacy of HQ–CX and explore its potential molecular targets. Furthermore, the intestinally absorbed chemical constituents of HQ–CX were identified by UPLC-Orbitrap-MS analysis, and its effects on neutrophil extracellular trap (NET) formation in vitro were evaluated through enzyme-linked immunosorbent assay, Western blot, and immunofluorescence assays. Results: In this study, HQ–CX not only alleviated symptoms associated with QDBS but also enhanced blood flow restoration in ischemic regions, thereby reducing infarct size in MCAO rats after ischemia. Transcriptomic analysis revealed that HQ–CX may exert neuroprotective effects by inhibiting NET formation, a potential therapeutic target for IS, through suppression of complement component 5a receptor 1, peptidyl arginine deiminase 4, and integrin subunit beta 3 expression. Furthermore, HQ–CX significantly reduced plasma levels of cell-free DNA and histone-DNA complexes in MCAO rats, and decreased the expression of myeloperoxidase and citrullinated histone H3 in the pia mater, cortex, and striatum of the ischemic hemisphere. Interestingly, HQ–CX failed to provide additional neuroprotection when NETs were degraded by deoxyribonuclease I, suggesting that its neuroprotective effects against ischemic injury are primarily mediated through inhibition of NET formation. Conclusion: HQ–CX exerts protective effects against IS by inhibiting NET formation through the complement component 5a/complement component 5a receptor 1 signaling pathway. These findings provide scientific evidence supporting the clinical efficacy of this herbal pair in the treatment of IS.

  • Open Access

    Integrated analysis of single-cell RNA sequencing, transcriptomics, and thermal proteome profiling identifies PLCG1 as the therapeutic target of isopimpinellin in treating rheumatoid arthritis

    by Huantian Cui, Ning Wang, Feitian Min, Huan Pei, Yuming Wang, Hanzhou Li, Qianqian Wan, Yan Meng, Mingwei He, Xiaoman Lv, et al.

    Isopimpinellin (ISOP), derived from Toddalia asiatica (L.) Lam, is thought to possess anti-inflammatory potential. However, the effects of ISOP on rheumato

  • Trifolirhizin alleviates bone destruction in rheumatoid arthritis by inhibiting osteoclast differentiation through the activation of FPR2

    by Jingbo Wang, Jinghang Yang, Qian Wang, Wanyi Guo, Siyu Li, Mingzhu Qi, Xiangying Kong, Xiaohui Su

  • Artesunate ameliorates leflunomide low-response against bone destruction in rheumatoid arthritis via cGMP-PKG signalling

    by Fengyu Huang, Peiping Chen, Xinzhuo Zhang, Jingbo Wang, Siyu Li, Changyue Song, Qian Wang, Daiyue Ding, Na Lin, Xiangying Kong, et al.

  • Open Access

    Mesothelin as a biomarker and potential therapeutic target in rheumatoid arthritis bone destruction

    by Xiaohui Su, Qian Wang, Jingbo Wang, Panpan Zhu, Wanyi Guo, Jinghang Yang, Siyu Li, Fengyu Huang, Mingzhu Qi, Hui Li, et al.


  • Open Access

    TMCO1 as an Endoplasmic Reticulum Calcium Load-Activated Channel: Mechanisms and Disease Implications

    by Jingbo Wang, Panpan Zhu, Zhuohang Li, Xiaohui Su, Mingzhu Qi, Aimin Zhou, Xiangying Kong

    Calcium ions (Ca2+) play a vital role in many biological processes. Transmembrane and coiled-coil domain 1 (TMCO1) has been characterized as an endoplasmic reticulum (ER) transmembrane protein in recent years. It keeps the cytoplasm and ER’s Ca2+ homeostasis stable by acting as a novel calcium channel. Studies from different laboratories have revealed that the mutation or deficiency of TMCO1 is closely correlated with several diseases, including cerebro-facio-thoracic dysplasia (CFTD), glaucoma, premature ovarian failure (POF), osteoporosis, and cancer. Here, we review the characteristics of TMCO1 and its involvement in related diseases, which may provide useful information for developing therapeutic strategies for these diseases, as well as promote further research on this protein.

  • Open Access

    Comparison of the Blood–Brain Barrier Penetration Ability and Anti-Neuroinflammatory Activity of Chromones in Two Types of Agarwood

    by Mengyuan Yang, Yanan Yuan, Jingfan Wei, Yifei Pei, Yuanfei Niu, Yifan Zhao, Xiangying Kong, Zhijie Zhang

    Background/Objectives: Agarwood has a good neuroprotective effect and is often used to relieve anxiety and treat insomnia. This study compared the similarities and differences in the chromone components of two types of agarwood. It further investigated the absorption and brain distribution characteristics of these components in rats and their neuroprotective effects mediated through anti-neuroinflammatory pathways. Methods: This study confirmed, through ITS2 barcoding and chloroplast genome analysis, that both the ordinary and Qi-Nan agarwood are derived from Aquilaria sinensis. A comparative analysis of chromones in ethanol extracts derived from ordinary and Qi-Nan agarwood, as well as those capable of penetrating the blood-brain barrier in vivo, was conducted using UPLC-Q-TOF-MS. Subsequently, an in vitro neuroinflammatory model was established via lipopolysaccharide (LPS)-stimulated BV-2 cells to evaluate the anti-neuroinflammatory activity of differential chromones. Results: UPLC-Q-TOF-MS characterization revealed the chromone components in the two types of agarwood: A total of 81 chromone compounds were identified in the ethanol extracts of ordinary agarwood (OAE) (20 THPECs, 42 FTPECs, and 19 BI), while 41 were identified in the ethanol extracts of Qi-Nan agarwood (QNE) (11 THPECs and 30 FTPECs). Pharmacokinetic analysis in rats showed that 14 components from OAE (eight THPECs and six FTPECs) penetrated the rat serum, and 10 of these 14 components penetrated the blood–brain barrier (BBB). Twelve FTPECs from QNE penetrated the rat serum, all of which penetrated the BBB. The total peak area of the total ion current (TIC) was calculated for the samples, and the TIC of the serum was compared to that of the brain tissue from the same rat to roughly estimate the ratio. The results demonstrated that the capability of FTPECs to traverse the blood–brain barrier is substantially superior to that of THPECs. Correspondingly, only FTPECs were detected using DESI-MS imaging; no THPECs were detected in rat brain tissue, and DESI-MS imaging localized FTPECs to neuroanatomic regions (cerebral cortex, thalamus, and hippocampus). In vitro neuroinflammatory assays revealed the superior anti-inflammatory efficacy of QNE over OAE (IL-6/TNF-α suppression, p < 0.05), correlating with its FTPEC-rich composition. Conclusions: Structure–activity relationships identified FTPECs as potent inhibitors of pro-inflammatory cytokines, exhibiting enhanced BBB penetration (blood–brain relative abundance > 1). These findings establish FTPECs as prioritized candidates for CNS-targeted therapeutics, with QNE’s pharmacological superiority attributed to its FTPEC dominance and optimized BBB transit capacity.


  • Open Access

    Glycosides of Tripterygium wilfordii Hook. F Inhibits Bone Loss in Rheumatoid Arthritis by Downregulating Interleukin-8/C-X-C Motif Chemokine Receptor 2 Signaling Pathway

    by Ya-Ge Tian, Li-Ling Liu, Ming-Zhu Qi, Jing-Hang Yang, Pan-Pan Zhu, Na Lin, Xiao-Hui Su, Xiang-Ying Kong

    Objective: The objective of this study was to investigate the effect of glycosides of Tripterygium wilfordii Hook. F (GTW) on bone erosion in collagen-induced arthritis (CIA) rats and osteoclastogenesis. Materials and Methods: The effects of GTW on bone destruction were assessed through hematoxylin and eosin analyses and tartrate-resistant acid phosphatase (TRAP) staining. In vitro, TRAP staining, F-actin, and quantitative polymerase chain reaction assays were used to evaluate the inhibitory effects of GTW on osteoclast differentiation. In addition, Western blot, immunohistochemistry, and immunofluorescence staining techniques were employed to explore the mechanisms of GTW by determining the expression of interleukin-8 (IL-8), C-X-C motif chemokine receptor 2 (CXCR2), nuclear factor of activated T cells 1 (NFATc1), and p65. Results: GTW slowed the onset of arthritis and reduced arthritis scores. Our mechanistic studies demonstrated that GTW reduced the number of osteoclasts in rats with CIA and significantly suppressed receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation, as evidenced by a decrease in TRAP-positive cells, alterations in F-actin rings, and modulation of osteoclast-specific gene expression. The inhibition of IL-8, CXCR2, NFATc1, and p65 activation by GTW was observed in both CIA rats and osteoclasts. Conversely, the introduction of IL-8 into the osteoclast culture system mitigated the effects of GTW on osteoclast differentiation. Conclusions: Our findings suggest that GTW suppressed osteoclastogenesis and bone loss by inhibiting the IL-8/CXCR2 signaling pathway. These results offer valuable insights into the potential therapeutic role of GTW in rheumatoid arthritis and lay the groundwork for future clinical applications.


  • Qingxin Jieyu Granule alleviates myocardial infarction through inhibiting neutrophil extracellular traps via activating ANXA1/FPR2 axis

    by Mingzhu Qi, Helan Huang, Zhuohang Li, Jianye Quan, Jingbo Wang, Fengyu Huang, Xinzhuo Zhang, Peiping Chen, An Liu, Zhuye Gao, et al.